-
-
-
-
-
-
-
Oppenheimer Downgrades Soleno Therapeutics Inc. (SLNO) to Perform
-
-
-
-
-
-
-
Neurocrine Biosciences nearing over $2.5B deal for Soleno Therapeutics
-
-
-
-
-
-
-
Soleno Therapeutics Inc. (SLNO) PT Lowered to $107 at Baird
-
-
-
-
-
-
-
Soleno Therapeutics, Inc. (SLNO) Tops Q3 EPS by 42c
-
-
-
-
-
-
-
ACAD failure eliminates a competitive threat to Soleno Therapeutics (SLNO) - Oppenheimer
-
-
-
-
-
-
-
TD Cowen on Soleno Therapeutics Inc. (SLNO): 'Patient Death Not Treatment Related; Vykat XR Safety Continues To Be Consistent'
-
-
-
-
-
-
-
Baird on Soleno Therapeutics Inc. (SLNO): 'Buyers on pullback following short report'
-
415,274 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

